Come Lepage

8PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 03, 2026
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.

Thomas Pierre Walter, Julien Mazieres, Josiane Otto

|Jun 20, 2025
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.

Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou

|Jan 31, 2025
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials.

Claire Gallois, Marine Sroussi, Thierry André

|Jun 26, 2024
How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology.

Elodie Martin, Karine Le Malicot, Catherine Guérin-Charbonnel

|Jun 10, 2024
Interference With VIP to Distinguish Between Real and False VIPoma: National Study From the French Endocrine Tumors Group.

Benjamin Chevalier, Delphine Bonnet, Come Lepage

|Apr 27, 2024
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).

Jean-Louis Legoux, Roger Faroux, Nicolas Barrière

Pageof 2

Frequent Collaborators

3 joint publications

Karine Le Malicot

2 joint publications

David Malka

2 joint publications

Anthony Turpin

2 joint publications

Thomas Walter